Table 3 Experience with insurance coverage issues and obtaining access to systemic bevacizumab for HOCF among HHT centers
Statement | Percent of Centers |
|---|---|
Able to obtain insurance coverage for most or all patients | 70% |
Obtaining insurance coverage is a cumbersome process for most patients | 50% |
Have obtained bevacizumab using âGenentech Access to Care Foundationâ compassionate use program | 20% |
Have had little or no trouble with Medicare approval of bevacizumab | 35% |
Able to obtain insurance coverage for oral anti-angiogenic therapies in cases of systemic bevacizumab insurance denial | 5% |
Frequently forced to search for alternative treatments because of insurance denial | 0% |